Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEADFAST: TX200-TR101 in Living Donor Kidney Transplant Recipients
NCT04817774Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Mar 2021
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
A Phase 2 trial of TX200 in kidney transplant rejection, sponsored by Sangamo Therapeutics. Started Mar 2021; status: completed.
02
Drugs
TX200
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04817774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817774.